奥美拉唑与莫沙必利联用对慢性胃炎病人降钙素原与胃泌素的影响

Influence of omeprazole combined with moxapride on procalcitonin and gastrin for patients with chronic gastritis

目的探讨奥美拉唑与莫沙必利联用对慢性胃炎(CG)病人降钙素原与胃泌素的影响。方法选取2016年5月至2018年5月深圳市龙岗区第二人民医院收治的CG病人96例,按照随机抽签法均分成观察组与对照组。对照组采用单纯莫沙必利治疗,观察组则在莫沙必利治疗的基础上增用奥美拉唑治疗。对比两组在临床疗效,治疗前后血清降钙素原与胃泌素水平,不良反应以及治疗前后生活质量等方面的差异。结果治疗总有效率方面,观察组高于对照组(95.83%比77.08%,P<0.01)。治疗后观察组与对照组在血清降钙素原[(0.83±0.57)µg/L比(1.44±0.82)µg/L]与胃泌素水平[(93.10±13.28)ng/L比(110.34±14.85)ng/L]比较,前者更低(均P<0.01)。观察组和对照组在腹泻、恶心呕吐及皮疹的不良反应发生率方面对比,均差异无统计学意义(P>0.05)。治疗后观察组与对照组在躯体功能、心理功能、物质生活及社会功能的生活质量评分方面对比,前者更高(均P<0.01)。结论奥美拉唑及莫沙必利联合应用于CG病人中可获得理想的临床疗效,同时可显著下调血清降钙素原与胃泌素水平,促进生活质量的提高。具有较佳的安全性,值得临床推广应用。

Objective To explore the influence of omeprazole combined with moxapride on procalcitonin and gastrin for patients with chronic gastritis(CG).Methods The 96 CG patients admitted to The Second People’ s Hospital of Longgang District from May2016 to May 2018 were recorded as the objects of observation,and were assigned into the observation group and the control group by random lottery.The control group was treated with moxapride alone,while the observation group was treated with omeprazole in addition to moxapride.The clinical efficacy,serum procalcitonin and gastrin levels,adverse reactions and quality of life before and after treatment were compared between the two groups.Results The total effective rate of treatment was higher in the observation group than in the control group(95.83% vs. 77.08%,P<0.01).After treatment,the serum levels of procalcitonin [(0.83±0.57) μg/L vs.(1.44±0.82) μg/L] and gastrin [(93.10±13.28) ng/L vs.(110.34±14.85) ng/L] were lower in the observation group than in the control group(both P<0.01).There were no significant differences in the incidences of adverse reactions including diarrhoea,nausea,vomiting and rash between the observation group and the control group(P>0.05).After treatment,the quality of life scores of body function,psychological function,material life and social function were higher in the observation group than the control group(both P<0.01).Conclusion The combined application of omeprazole and moxapride in CG patients can achieve ideal clinical efficacy,and meanwhile,significantly reduce serum procalcitonin and gastrin levels and promote quality of life,which has better safety and is worthy of clinical application.